Dopamine

Dopamine Manufacturers

• Apotheca Company
  

  ×

  Dopamine | Apotheca Company

  

  ---

  SUGGESTED DOSAGE:  10 drops orally, 3 times a day.  Consult a physician for use in children under 12 years of age.
  

  Close
  No Recall

  More Info
• Apotheca Company
  

  ×

  Dopamine | Apotheca Company

  

  ---

  DIRECTIONS:  1-10 drops under the tongue, 3 times a day or as directed by a health professional.  Consult a physician for use in children under 12 years of age.

  
  

  Close
  No Recall

  More Info
• General Injectables & Vaccines, Inc
  

  ×

  Dopamine | General Injectables & Vaccines, Inc

  

  ---

  WARNING: This is a potent drug: It must be diluted before administration to patient.
  Suggested Dilution: Transfer contents of one or more ampuls or vials by aseptic technique to either 250 mL or 500 mL of one of the following sterile intravenous solutions:

  1. Sodium Chloride Injection, USP
  
  2. Dextrose (5%) Injection, USP

  3. Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP

  4. 5% Dextrose in 0.45% Sodium Chloride Solution

  5. Dextrose (5%) in Lactated Ringer's Solution

  6. Sodium Lactate (# Molar) Injection, USP

  7. Lactated Ringer's Injection, USP

  DOPAMINE has been found to be stable for a minimum of 24 hours after dilution in the sterile intravenous solutions listed above. However, as with all intravenous admixtures, dilution should be made just prior to administration. Do NOT add DOPAMINE Injection to Sodium Bicarbonate or other alkaline intravenous solutions, since the drug is inactivated in alkaline solution. Mixing of dopamine with alteplase in the same container should be avoided as visible particulate matter has been observed. It is recommended that dopamine not be added to amphotericin B solutions because amphotericin B is physically unstable in dopamine-containing solutions.
  Rate of Administration: DOPAMINE, after dilution, is administered intravenously through a suitable intravenous catheter or needle. An i.v. drip chamber or other suitable metering device is essential for controlling the rate of flow in drops/minute. Each patient must be individually titrated to the desired hemodynamic and/or renal response with DOPAMINE. In titrating to the desired increase in systolic blood pressure, the optimum dosage rate for renal response may be exceeded, thus necessitating a reduction in rate after the hemodynamic condition is stabilized. Administration rates greater than 50 mcg/kg/minute have safely been used in advanced circulatory decompensation states. If unnecessary fluid expansion is of concern, adjustment of drug concentration may be preferred over increasing the flow rate of a less concentrated dilution.

  Suggested Regimen:

  1. When appropriate, increase blood volume with whole blood or plasma until central venous pressure is 10 to 15 cm H2O or pulmonary wedge pressure is 14-18 mm Hg.

  2. Begin administration of diluted solution at doses of 2-5 mcg/kg/minute DOPAMINE in patients who are likely to respond to modest increments of heart force and renal perfusion.
  In more seriously ill patients, begin administration of diluted solution at doses of 5 mcg/kg/minute DOPAMINE and increase gradually, using 5 to 10 mcg/kg/minute increments, up to 20 to 50 mcg/kg/minute as needed. If doses of DOPAMINE in excess of 50 mcg/kg/minute are required, it is suggested that urine output be checked frequently. Should the urine flow begin to decrease in the absence of hypotension, reduction of DOPAMINE dosage should be considered. Multiclinic trials have shown that more than 50% of the patients were satisfactorily maintained on doses of DOPAMINE less than 20 mcg/kg/minute. In patients who do not respond to these doses with adequate arterial pressures or urine flow, additional increments of DOPAMINE may be employed in an effort to produce an appropriate arterial pressure and central perfusion.

  3. Treatment of all patients requires constant evaluation of therapy in terms of the blood volume, augmentation of myocardial contractility, and distribution of peripheral perfusion. Dosage of DOPAMINE should be adjusted according to the patient's response, with particular attention to diminution of established urine flow rate, increasing tachycardia or development of new
  dysrhythmias as indices for decreasing or temporarily suspending the dosage.
  

  4. As with all potent intravenously administered drugs, care should be taken to control the rate of administration so as to avoid inadvertent administration of a bolus of drug.
  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Close
  No Recall

  More Info
• Bioactive Nutritional, Inc.
  

  ×

  Dopamine | Ranbaxy Laboratories Inc.

  

  ---

  Apply a thin film of 0.1% HALOG OINTMENT (Halcinonide Ointment, USP) to the affected area two to three times daily.

  Occlusive Dressing Technique

  Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply HALOG OINTMENT under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

  If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  Occlusive Dressing Technique

  Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply HALOG OINTMENT under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

  If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  Close
  No Recall

  More Info
• Deseret Biologicals, Inc.
  

  ×

  Dopamine | Deseret Biologicals, Inc.

  

  ---

  1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

  Close
  No Recall

  More Info
• Deseret Biologicals, Inc.
  

  ×

  Dopamine | Deseret Biologicals, Inc.

  

  ---

  1-10 drops under the tounge, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

  Close
  No Recall

  More Info
• Bioactive Nutritional, Inc.
  

  ×

  Dopamine | Bioactive Nutritional, Inc.

  

  ---

  10 drops orally, 3 times a day.  Consult a physician for use in children under 12 years of age.

  Close
  No Recall

  More Info
• Bioactive Nutritional, Inc.
  

  ×

  Dopamine | Bioactive Nutritional, Inc.

  

  ---

  10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.

  Close
  No Recall

  More Info